BSX gives first EVOLVE II treatment

Boston Scientific Corporation (NYSE:BSX) has begun its first EVOLVE II clinical trial. The trial is intended to evaluate the safety and effectiveness of the SYNERGY Stent System and support US Food and Drug Administration (FDA) approvals. It also aims to attain Japanese regulatory approvals for the treatment of atherosclerotic coronary lesions.

It was forecasted that this program will enroll about 2000 patients at up to 160 sites globally, that includes the United States, Canada, Europe, Australia, New Zealand, Japan, India, Brazil and Singapore. They are treating the first patient at the Christ Hospital, Lindner Research Centre in Cincinnati, Ohio.

CE Mark approved the healthcare center for the SYNERGY Stent System in November. The SYNERGY Stent uses the market-leading everolimus drug and features an ultra-thin bioabsorbable polymer covering. The absorption of the polymer is finished soon after the drug elution is completed at the end of 12 weeks.

Boston Scientific Corporation (NYSE:BSX) total value after the recent close was $7.61 billion and the enterprise value according to Yahoo data was $11.51 billion. The previous 12 month price to sales ratio was 1.05. The company showed -55.27% as a profit margin in the last twelve months and an operating margin at -52.41%. Return on equity was -43.84% for the last twelve months. Return on assets was -20.95%.

Taking a look at some competitors, the total value of Abbott Laboratories (NYSE:ABT) in the stock market was $102.74 billion and the takeover value of the company was $107.52 billion. The last twelve month price to sales ratio for the company was 2.61. It had a 16.56% profit margin in the last twelve months and an operating margin at 19.67%. Return on assets was 10.62%.

The total value of Johnson & Johnson (NYSE:JNJ) after the latest trading session was $193.24 billion and their enterprise value was $190.32 billion. The prior 52 week price to sales ratio was 2.93. The company recorded a profit margin of 12.39% for the prior 12 months and had an operating margin of 16.68%. Return on equity for this stock was 13.58% while return on assets appeared at 7.08%.

Medtronic, Inc. (NYSE:MDT) market capitalization after the most recent trading session was $42.93 billion and the enterprise value was $51.70 billion. Price to sales ratio for the prior 52 weeks was 2.63.